ProKidney Q1 net loss $42.6M; Phase 3 PROACT 1 enrollment on track for mid-2026

PROKIDNEY CORP.

Net loss $42.6M for Q1 2026; cash & equivalents $224.9M supporting operations into mid-2027.
Phase 3 PROACT 1 enrollment on track to complete mid-2026; pivotal topline results expected Q2 2027.
FDA confirmed eGFR slope as surrogate endpoint for accelerated approval under RMAT designation.
Phase 2 REGEN-007 showed 4.6 mL/min/1.73m² improvement in annual eGFR slope decline.
R&D expenses $33.8M (+24% YoY) driven by PROACT 1; G&A expenses $11.3M (-21% YoY).

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

PROKIDNEY CORP. reported the first quarter ended March 31, 2026 results: net income Net loss before noncontrolling interest was $42.6 million.

Period: the first quarter ended March 31, 2026
Net income: Net loss before noncontrolling interest was $42.6 million
Result: reported results

Exact text from the filing

ProKidney Corp. (the "Company") issued a press release to announce its financial results for the quarter ended March 31, 2026.

View on SEC.gov

Browse all earnings releases →

PROKIDNEY CORP. filing history →

Source: SEC EDGAR

accession 0001193125-26-225848

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.